Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

DORIS definition of remission in SLE: final recommendations from an international task force

Mosca M;
2021-01-01

Abstract

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
2021
van Vollenhoven, Rf; Bertsias, G; Doria, A; Isenberg, D; Morand, E; Petri, Ma; Pons-Estel, Ba; Rahman, A; Ugarte-Gil, Mf; Voskuyl, A; Arnaud, L; Bruce, In; Cervera, R; Costedoat-Chalumeau, N; Gordon, C; Houssiau, Fa; Mosca, M; Schneider, M; Ward, Mm; Alarcon, G; Aringer, M; Askenase, A; Bae, Sc; Bootsma, H; Boumpas, Dt; Brunner, H; Clarke, Ae; Coney, C; Czirják, L; Dörner, T; Faria, R; Fischer, R; Fritsch-Stork, R; Inanc, M; Jacobsen, S; Jayne, D; Kuhn, A; van Leeuw, B; Limper, M; Mariette, X; Navarra, S; Nikpour, M; Olesinska, Mh; Pons-Estel, G; Romero-Diaz, J; Rubio, B; Schoenfeld, Y; Bonfá, E; Smolen, J; Teng, Yko; Tincani, A; Tsang-A-Sjoe, M; Vasconcelos, C; Voss, A; Werth, Vp; Zakharhova, E; Aranow, C
File in questo prodotto:
File Dimensione Formato  
e000538.full.pdf

accesso aperto

Tipologia: Versione finale editoriale
Licenza: Creative commons
Dimensione 1.03 MB
Formato Adobe PDF
1.03 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1113156
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 87
  • ???jsp.display-item.citation.isi??? 92
social impact